- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02343419
Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Methacholine Challenge Test
Diagnostic Utility of Different Airway Resistance Assessment Techniques in the Evaluation of Bronchial Hyperreactivity by Methacholine Challenge Testing
The aim of the study is to compare standard spirometric evaluation of methacholine challenge test with plethysmographic, interrupter technique and forced oscillation technique (FOT) evaluation of the airways resistance.
The study group will consist of patients referred for methacholine challenge test. All patient will undergo spirometric, plethysmographic, interrupter technique and FOT examinations - before and after inhalation of aerosols. Patients will also undergo the measurement of nitric oxide concentration in exhaled air and laboratory tests, including: blood count, measurement of serum C-reactive protein, sodium, potassium, creatinine, immunoglobulin E and N-Terminal pro-brain natriuretic peptide (NT-proBNP) concentration.
The investigators intend to assess, if plethysmographic, and/or interrupter, and/or FOT measurement of bronchial reactivity can replace standard spirometric assessment. Plethysmography, interrupter technique and FOT are much more easier to perform for patients. Furthermore, those two techniques are less dependent on patient's motivation and cooperation ability. Thus, usage of FOT, interrupter technique and/or plethysmography in bronchial hyperreactivity testing could make methacholine challenge test more comfortable and available for more patients. The investigators are also going to analyze the relationship between exhaled nitric oxide and functional indices of bronchial hyperreactivity.
Study Overview
Status
Intervention / Treatment
Detailed Description
Bronchial hyperreactivity is defined as the increased respiratory tract responsiveness to multiple stimuli, which results in bronchial muscles constriction and bronchial lumen narrowing. Bronchial hyperreactivity is a hallmark of asthma, however it may also be present in other diseases, e.g. chronic obstructive pulmonary disease (COPD). Methacholine challenge test is one of the bronchial reactivity assessment methods. Methacholine acts directly on bronchial smooth muscles receptors and causes bronchoconstriction. Bronchial reactivity is increased in the presence of active inflammation. Methacholine challenge testing is commonly performed in patients with symptoms suggestive of asthma and negative result of spirometry reversibility test. The measurement of methacholine concentration which causes 20% forced expiratory volume at one second (FEV1) decrease in post-inhalation spirometry (PC20) is a standard method of hyperreactivity evaluation. However, above method could be used among patients who are able to perform acceptable spirometry. Furthermore, results of spirometry might be influenced by level of compliance and motivation of patients. Moreover, whereas spirometric methacholine challenge test has high negative predictive values, its positive predictive value is relatively low. Thus, diagnostic utility of other pulmonary function tests should be assessed in methacholine challenge test evaluation.
In plethysmography airway resistance is performed during tidal breathing. The increase of specific airway resistance of 200% and the decrease of specific airway conductance of 40% after methacholine inhalation, respectively, are proposed as a cut-off levels for bronchial hyperreactivity diagnosis.
In forced oscillation technique (FOT), sinusoidal oscillations are emitted by membrane into airway lumen and airway resistance is calculated on the basis of changes in air flow induced by oscillations. The increase of resistance and decrease of reactance in FOT are typical for bronchoconstriction.
Finally, also interrupter technique (IT) allows for airway resistance assessment during tidal breathing. In IT, airway resistance is calculated on the basis of mouth pressure measured directly after airway occlusion and airflow measured directly before occlusion.
The aim of the study is to compare standard spirometric evaluation of methacholine challenge test with plethysmographic, interrupter technique and forced oscillation technique (FOT) evaluation of the airways resistance.
All patient will undergo:
- clinical examination
- measurement of nitric oxide concentration in exhaled air
- spirometric, plethysmographic, interrupter technique and FOT examinations - before inhalation and after inhalation of aerosols
- following laboratory tests: blood count, measurement of serum C-reactive protein (CRP), sodium, potassium, creatinine, immunoglobulin E and NT-proBNP concentration
Patients will be provided with written and spoken information about study protocol. Written informed consent will be obtained from every patient.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Mazowieckie
-
Warsaw, Mazowieckie, Poland, 02-097
- Department of Internal Medicine, Pneumonology and Allergy, Medical University of Warsaw
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- presence of asthma symptoms without confirmation of diagnosis by standard methods
- dyspnea and/or cough of unknown etiology
Exclusion Criteria:
- FEV1 <1.2 L or <60% of predicted value
- acute heart failure
- myocardial infarction in last 3 months
- transient ischaemic attack or stroke in last 3 months
- aneurysms
- methacholine allergy
- pregnant and lactating women
- administration of β2-mimetic, anticholinergic agent or theophylline before methacholine challenge test in 6, 8 and 24 hours, respectively
- respiratory tract infection in last 6 weeks
- patient inability to cooperate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Bronchial challenge test
Patients will undergo Methacholine Challenge Test assessed by forced oscillation technique (FOT), plethysmography, interrupter technique and spirometry.
|
Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml. In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The concentration of methacholine inducing a 20% fall in FEV(1) from post-diluent baseline [PC(20)]
Time Frame: up to 2 hours
|
In case of FEV1 decrease of > 20% from baseline PC (20) will be calculated by logarithmic interpolation.
|
up to 2 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in FOT resistance and reactance from post-diluent baseline after inhalating consecutive methacholine aerosols
Time Frame: within 6 minutes after methacholine aerosol inhalation
|
Airway resistance and reactance will be measured by FOT after inhalating methacholine aerosols until FEV(1) fall of >20% from baseline
|
within 6 minutes after methacholine aerosol inhalation
|
Change in plethysmographic airway resistance from post-diluent baseline after inhalating consecutive methacholine aerosols
Time Frame: within 6 minutes after methacholine aerosol inhalation
|
Airway resistance will be measured by plethysmography after inhalating methacholine aerosols until FEV(1) fall of >20% from baseline
|
within 6 minutes after methacholine aerosol inhalation
|
Change in interrupter airway resistance from post-diluent baseline after inhalating consecutive methacholine aerosols
Time Frame: within 6 minutes after methacholine aerosol inhalation
|
Airway resistance will be measured by interrupter technique after inhalating methacholine aerosols until FEV(1) fall of >20% from baseline
|
within 6 minutes after methacholine aerosol inhalation
|
Change in FEV(1) from from post-diluent baseline after inhalating consecutive methacholine aerosols
Time Frame: within 6 minutes after methacholine aerosol inhalation
|
FEV (1) will be measured by spirometry after inhalating methacholine aerosols until FEV(1) fall of >20% from baseline
|
within 6 minutes after methacholine aerosol inhalation
|
Assessment of the difficulty level of FOT
Time Frame: after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Patients will receive visual analogue scale form assessing difficulty level and problems related to performing each test
|
after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Assessment of the difficulty level of plethysmography
Time Frame: after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Patients will receive visual analogue scale form assessing difficulty level and problems related to performing each test
|
after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Assessment of the difficulty level of interrupter technique
Time Frame: after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Patients will receive visual analogue scale form assessing difficulty level and problems related to performing each test
|
after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Assessment of the difficulty level of spirometry
Time Frame: after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Patients will receive visual analogue scale form assessing difficulty level and problems related to performing each test
|
after methacholine challenge test (up to 2 hours two hours from the start of the methacholine challenge test)
|
Duration of the bronchial resistance assessment by FOT
Time Frame: During methacholine challenge test (up to 2 hours)
|
Duration of each pulmonary function test will be measured
|
During methacholine challenge test (up to 2 hours)
|
Duration of the bronchial resistance assessment by plethysmography
Time Frame: During methacholine challenge test (up to 2 hours)
|
Duration of each pulmonary function test will be measured
|
During methacholine challenge test (up to 2 hours)
|
Duration of the bronchial resistance assessment by interrupter technique
Time Frame: During methacholine challenge test (up to 2 hours)
|
Duration of each pulmonary function test will be measured
|
During methacholine challenge test (up to 2 hours)
|
Duration of spirometry
Time Frame: During methacholine challenge test (up to 2 hours)
|
Duration of each pulmonary function test will be measured
|
During methacholine challenge test (up to 2 hours)
|
Total duration of methacholine challenge test
Time Frame: During methacholine challenge test (up to 2 hours)
|
Total duration bronchial challenge will be measured
|
During methacholine challenge test (up to 2 hours)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of nitric oxide concentration in exhaled air
Time Frame: Participanst will undergo measurement of nitric oxide concentration in exhaled air immediately before bronchial challenge test, total time of measurement: approximately 10 minutes
|
Nitric oxide concentration in exhaled air will be measured once, immediately before performing methacholine challenge test
|
Participanst will undergo measurement of nitric oxide concentration in exhaled air immediately before bronchial challenge test, total time of measurement: approximately 10 minutes
|
Laboratory tests
Time Frame: Patients will undergo laboratory tests once before perfoming methacholine challenge test; maximum period between the methacholine challenge test and performing laboratory tests: one month
|
Following laboratory tests will be performed: blood count, measurement of serum C-reactive protein, sodium, potassium, creatinine, immunoglobulin E and NT-proBNP concentration
|
Patients will undergo laboratory tests once before perfoming methacholine challenge test; maximum period between the methacholine challenge test and performing laboratory tests: one month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tomasz A Urbankowski, MD, Department of Internal Medicine, Pneumonology and Allergy, Medical University of Warsaw
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Bronchial Diseases
- Bronchial Hyperreactivity
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Agents
- Cholinergic Agonists
- Respiratory System Agents
- Miotics
- Parasympathomimetics
- Bronchoconstrictor Agents
- Muscarinic Agonists
- Methacholine Chloride
Other Study ID Numbers
- PFT-DIMPA-WUM1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchial Hyperreactivity
-
Federal State Budgetary Institution, Pulmonology...Moscow State University of Medicine and Dentistry; National Medical Research... and other collaboratorsUnknownHealth, Subjective | Hyperreactivity, BronchialRussian Federation
-
Hospital General Universitario Gregorio MarañonCompletedBronchial Hyperreactivity | Inhalant UseSpain
-
Allergi- og Lungeklinikken, ElsinoreNot yet recruitingBronchial Hyperreactivity
-
Centre Hospitalier Universitaire Saint PierreCompletedAsthma | Bronchial HyperresponsivenessBelgium
-
Rambam Health Care CampusTeva Branded Pharmaceutical Products R&D, Inc.CompletedAsthma | Bronchial HyperresponsivenessIsrael
-
Rambam Health Care CampusCompleted
-
SunovionCompletedReactive Airways Disease (RAD)United States, Canada
-
Johann Wolfgang Goethe University HospitalCompletedHouse Dust Mite Allergy | Bronchial HyperresponsivenessGermany
-
Rambam Health Care CampusCompletedBronchial Hyperreactivity | Infant, PrematureIsrael
-
Wolfson Medical CenterCompleted
Clinical Trials on Methacholine Challenge Test
-
Prescott WoodruffNational Institute of Allergy and Infectious Diseases (NIAID)Completed
-
Dr. Diane LougheedThe Ontario Thoracic Society of the Ontario Lung Association; Queen's University...CompletedAsthma | Cough Variant AsthmaCanada
-
Rambam Health Care CampusCompleted
-
Rambam Health Care CampusCompletedAsthma | Vitamin D Resistant RicketsIsrael
-
Johann Wolfgang Goethe University HospitalCompleted
-
Guy's and St Thomas' NHS Foundation TrustKing's College LondonRecruiting
-
Great Ormond Street Hospital for Children NHS Foundation...University College, LondonCompletedNeuromuscular Diseases | Central HypoventilationUnited Kingdom
-
US Department of Veterans AffairsEmory UniversityCompletedType 2 Diabetes Mellitus | Prediabetic StateUnited States
-
Shield TherapeuticsCompletedCrohn's Disease | Inflammatory Bowel Disease | Iron Deficiency Anaemia